Loading clinical trials...
Loading clinical trials...
The Efficacy and Safety of Zanubrutinib, Obinutuzumab and Lenalidomide (ZGR) Regimen in High-risk Treatment-naive Patients with Follicular Lymphoma
This is a prospective, multiple-centers, open-label, single-arm clinical study designed to evaluate the efficacy and safety of Zanubrutinib, Obinutuzumab, and Lenalidomide (ZGR) in high-risk treatment-naive patients with follicular lymphomas
Age
18 - No limit years
Sex
ALL
Healthy Volunteers
No
Ruijin Hospital, Shanghai Jiao Tong University School of Medicine
Shanghai, China
Start Date
December 1, 2024
Primary Completion Date
December 1, 2026
Completion Date
December 31, 2026
Last Updated
October 15, 2024
66
ESTIMATED participants
Zanubrutinib, Obinutuzumab and Lenalidomide (ZGR)
DRUG
Lead Sponsor
Ruijin Hospital
NCT06337318
NCT05006716
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions